Amgen Inc.

Other

Synergen, Inc.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

University of Colorado

The University of North Carolina at Chapel Hill

The United States of America As Represented by the Department of Health

Amgen Boulder Inc.

Angen Inc.

Synergen Biologicals, Inc.

Robert C Thompson

Stephen P Eisenberg

Michael T Brewer

Tadahiko Kohno

Charles H Hannum

Fenneke G Joslin

Gary L Stetler

Pradip K Bandyopadhyay

William P Arend

Andreas Sommer

Sharon M Wahl

Stephen P Eisenburg

Kjell Ohlsson

Richard W Perkins

Rebecca W Vanderslice

David F Carmichael

Charles C Squires

David J Dripps

Robert Hageman

David Dripps

Ronald Evans

Henryk Cudny

Harry S Miley

Charles W Hubbard

James Vannice

Walker H Busby, Jr

Michael W King

David R Clemmons

Karin K Hale

Methods and pharmaceutical compositions are provided to prevent retroviral infections of host cells. More particularly, the invention relates to prevention of HIV infection of human cells by serine leukocyte protease inhibitor (SLPI).

Inhibition of retrovirus infection

Compounds are disclosed having the general formula R&#x2014;X&#x2014;R, wherein Rand Rare biologically active groups, at least one of which is polypeptidic. X is a non-peptidic polymeric group. Rand Rmay be the same or different. Preferred Rand Rgroups are interleukin-1 receptor antagonist, 30 kDa TNF inhibitor, interleukin-2 receptors and CR1 and muteins thereof. Also included are site selectively modified interleukin-1 receptor antagonist and 30 kDa TNF inhibitor.

Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors

Interleukin-1 inhibitors are provided. Compositions comprising an interleukin-1 inhibitor are provided. Methods of treating a patient comprising administering an interleukin-1 inhibitor are provided.

Interleukin-1 inhibitors, compositions, and methods of treatment

Compounds are disclosed having the general formula R -X-R , wherein R and R are biologically active groups, at least one of which is polypeptidic. X is a non-peptidic polymeric group. R and R may be the same or different. Preferred R and R groups are TNF inhibitors.

PEGylation reagents and compounds formed therewith

The present invention provides nucleic acid molecules encoding a 30kDa TNF inhibitor or a fragment thereof having at least one non-native cysteine residue at the N-terminus, C-terminus, residue 14, or residue 15.

Nucleic acids encoding TNF inhibitor and method of production

A synthetic DNA sequence and its genetic equivalents are disclosed which sequences are capable, when used in a recombinant DNA method, of directing production of a serine protease inibitor protein. Recombinant DNA methods for the production of serine protease inhibitor proteins are also disclosed. These methods incorporate either the synthetic DNA sequence of the present invention or natural DNA sequences isolated from human cDNA or genomic libraries.

Recombinant methods for production of serine protease inhibitors and DNA sequences

The present invention provides methods for treating interleukin-1 mediated diseases including arthritis, inflammatory bowel disease, sepsis and septic shock, ischemia injury, reperfusion injury, multiple sclerosis and cerebral infarctions such as cerebral palsy. The methods are accomplished by administering to a patient in need thereof a therapeutically effective amount of an interleukin-1 inhibitor.

Method for treating interleukin-1 mediated diseases

At least two substantially purified tumor necrosis factor (TNF) inhibitors are disclosed which are glycoproteins that are active against TNF. The isolation of 3O kDa and 40 KDa TNF inhibitor from urine is disclosed. The deglycosylated form of the 3O kDa TNF inhibitor and 40 kDa TNF inhibitor are described as being active against TNF. The 40 kDa TNF inhibitor is active against both TNF alpha a TNF beta. The amino acid sequence of the 30 kDa TNF inhibitor and the 40 kDa TNF inhibitor are disclosed. Methods for isolating the TNF inhibitors from human U937 cell medium and producing the proteins by recombinant-DNA methods are also described.

Tumor necrosis factor (TNF) inhibitor and method for obtaining the same

A synthetic DNA sequence and its genetic equivalents are disclosed which sequences are capable, when used in a recombinant DNA method, of directing production of a serine protease inibitor protein. Recombinant DNA methods for the production of serine protease inhibitor proteins are also disclosed. These methods incorporate either the synthetic DNA sequence of the present invention or natural DNA sequences isolated from human cDNA or genomic libraries. In addition, a single polypeptide chain protein is disclosed which is capable of inhibiting chymotrypsin and elastase but not trypsin. In one embodiment, this protein is a shortened from (single domain) of the protein produced by the method described herein.

Recombinant methods for production of serine protease inhibitors and DNA

Insulin-like growth factor I and II binding protein have potentiating and inhibiting activities. Cloning vectors and portable DNA sequences are disclosed.

Method for potentiating and inhibiting insulin-like growth factor

Analogs of the serine protease inhibitors in which the amino acid sequence is varied slightly are disclosed, which analogs variously show improved properties including improved resistance to oxidative inactivation, improved ability to inhibit pancreatic elastase, improved ability to inhibit cathepsin G, and improved ability to inhibit trypsin.

Serine protease inhibitor analogs

Recombinant methods for production of serine inhibitors and DNA

Disclosed is an apparatus for automatically consolidating a filter or, more specifically, an apparatus for drawing a volume of gas through a plurality of sections of a filter, whereafter the sections are subsequently combined for the purpose of simultaneously interrogating the sections to detect the presence of a contaminant.

Filter type gas sampler with filter consolidation

A method for the production of commercial quantities of highly purified interleukin-1 inhibitor (IL-1i) from a recombinant host is disclosed. A preferred recombinant E. coli host for use in this method is also disclosed.

Production of recombinant human interleukin-1 inhibitor

Growing community of inventors

Boulder, CO, United States of America

Robert C Thompson